Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain

Acta Paediatrica, International Journal of Paediatrics

Volumn 106, Issue 11, 2017, Pages 1857-1862

  Maragkoudaki, M ^a   Chouliaras, G ^a   Orel, R ^b   Horvath, A ^c   Szajewska, H ^c   Papadopoulou, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Functional abdominal pain; Lactobacillus reuteri; Pain relief; Placebo; Probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL PAIN; ABSENTEEISM; AGE; ARTICLE; CHEWABLE TABLET; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG USE; FACES PAIN SCALE; FEMALE; GASTROINTESTINAL SYMPTOM; GREECE; HUMAN; LACTOBACILLUS REUTERI; MAJOR CLINICAL STUDY; MALE; PAIN INTENSITY; POLAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCHOOL ATTENDANCE; SCHOOL CHILD; SEX DIFFERENCE; SLOVENIA; VISUAL ANALOG SCALE; ADOLESCENT; PRESCHOOL CHILD;

ABDOMINAL PAIN; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTOBACILLUS REUTERI; MALE; PROBIOTICS;

EID: 85028414891     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.13992     Document Type: Article

References (30)

1. Scarpato Ε, Kolacek S, Konjik V, Jojkic-Pavkov D, Riechmann ER, Kostovski A, et al. Functional gastrointestinal disorders in children and adolescents from the European Mediterranean area: a prevalence study. J Pediatr Gastroenterol Nutr 2017; 64(Suppl 1): 59.
2. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006; 130: 1527–37.
3. Saps M, Seshadri R, Sztainberg M, Schaffer G, Marshall BM, Di Lorenzo CA. A prospective school based study of abdominal pain and other common somatic complaints in children. J Pediatr 2009; 154: 322–6.
4. Dhroove G, Chogle A, Saps M. A million-dollar work-up for abdominal pain: is it worth it? J Pediatr Gastroenterol Nutr 2010; 51: 579–83.
5. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033–49.
6. Romano C, Ferrau V, Cavatio F, Iacono G, Spina M, Lionetti E, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014; 50: 68–71.
7. Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: a randomized, double-blind. Placebo-controlled trial. J Pediatr 2016; 174: 160–4.
8. Eftekhari K, Vahedi Z, Kamali Aghdam M, Noemi Diaz D. A randomized double-blind placebo-controlled trial of Lactobacillus reuteri for chronic functional abdominal pain in children. Iran J Pediatr 2015; 25: 2616.
9. Chaussain M, Kheddari K, Roche R, Giusti B, Habib F, Badoual J, et al. Abdominal pain in children caused by lactose intolerance. Prospective use of the hydrogen breath test. Presse Med 1994; 23: 881–5.
10. Gijsbers CF, Kneepkens CM, Buller HA. Lactose and fructose malabsorption in children with recurrent abdominal pain: results of double-blinded testing. Acta Paediatr 2012; 101: 411–5.
11. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatric Nursing 1988; 14: 9–17.
12. Svedlund J, Sjödin I, Dotevall G. GSRS-A clinical rating score for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129–34.
13. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome: a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925–31.
14. Romano C, Ferrau V, Cavatio F, Iacono G, Spina M, Lionetti E, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health 2014; 50: e68–71.
15. Kisaalita N, Staud R, Hurley R, Robinson M. Placebo use in pain management: the role of medical context, treatment efficacy and deception in determining placebo acceptability. Pain 2014; 155: 2638–45.
16. Kisaalita NR, Roditi D, Robinson ME. Factors affecting placebo acceptability: deception, outcome, and disease severity. J Pain 2011; 12: 920–8.
17. Colloca L, Benedetti F. Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 2005; 6: 545–52.
18. Vase L, Robinson ME, Verne GN, Price DD. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005; 115: 338–47.
19. Lewis DW, Kellstein D, Dahl G, Burke B, Frank LM, Toor S, et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache 2002; 42: 780–6.
20. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332–40.
21. Saps M, Youssef N, Miranda A, Nurko S, Hyman P, Cocjin J, et al. Multicenter, randomized placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009; 137: 1261–9.
22. Russell AC, Stone AL, Walker LS. Nausea in children with functional abdominal pain predicts poor health outcomes in young adulthood. Clin Gastroenterol Hepatol 2016; 15: 706–11.
23. Indrio F, Riezzo G, Raimondi F, Bisceglia M, Cavallo L, Francavilla R. The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J Pediatr 2008; 152: 801–6.
24. Indrio F, Riezzo G, Raimondi F, Bisceglia M, Cavallo L, Francavilla R. Effects of probiotic and prebiotic on gastrointestinal motility in newborns. J Physiol Pharmacol 2009; 6: 27–31.
25. Indrio F, Riezzo G, Raimondi F, Bisceglia M, Filannino A, Cavallo L, et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Invest 2011; 41: 417–22.
26. Kunze WA, Mao YK, Wang B, Huizinga JD, Ma X, Forsythe P, et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med 2009; 13: 2261–70.
27. Ma X, Mao YK, Wang B, Huizinga JD, Bienenstock J, Kunze W. Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am J Physiol Gastroenterol Liver Physiol 2009; 296: 868–75.
28. Wang B, Mao YK, Dorio C, Pasyk M, Wu RY, Bienenstock J, et al. Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes. FASEB J 2010; 24: 4078–88.
29. Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil 2010; 23: 255–64.
30. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potent biomarker? Gastroenterology 2006; 130: 304–11.